Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28529947
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Stem+Cell+Investig
2017 ; 4
(ä): 32
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Immune checkpoint blockade for hematologic malignancies: a review
#MMPMID28529947
Pianko MJ
; Liu Y
; Bagchi S
; Lesokhin AM
Stem Cell Investig
2017[]; 4
(ä): 32
PMID28529947
show ga
Immune checkpoint blockade has revolutionized the treatment of cancer, with
impressive responses seen in a broad variety of tumor types. Blockade of immune
checkpoints and immune signaling antibodies has shown promise in multiple types
of hematologic malignancies (HMs), with dramatic single agent responses for
pembrolizumab and nivolumab in Hodgkin lymphoma (HL). In this review, we outline
the current state of immune checkpoint blockade drug development in HMs, and
discuss mechanisms of activity and resistance, and highlight potential targets in
the immune tumor microenvironment (TME). Blockade of T-cell checkpoint molecules
PD-1/PD-L1 and CTLA-4 are the most clinically mature of the immune checkpoint
strategies. Novel and upcoming strategies for immune checkpoint blockade drug
development in HMs using innovative combinations to modulate immunologic targets
shows significant promise as a way to expand the number of patients with blood
cancers who could benefit from immunotherapy.